HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model. [electronic resource]
Producer: 20200302Description: 48 p. digitalISSN:- 1550-7416
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Carboplatin -- pharmacology
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Female
- Half-Life
- Humans
- Mice
- Ovarian Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- pharmacology
- Receptor, ErbB-3 -- antagonists & inhibitors
- Recombinant Fusion Proteins -- pharmacology
- Treatment Outcome
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.